NCT06627114Completed
Effectiveness of Nutrition Education Program and Omega-3 Supplementation Among Non-alcoholic Fatty Liver Disease Patients
Effectiveness of Nutrition Education Program and Omega-3 Supplementation on Body Weight, Liver Enzymes, Lipid Profile Among Non-Alcoholic Fatty Liver Disease Patients
Source: ClinicalTrials.gov · Last updated 29 Jun 2026
Brief summary (registry, in English)
The aim of this clinical trial is to examine the impact of nutritional education and omega-3 supplementation in influencing body weight, liver enzyme levels, and lipid profiles in patients diagnosed with non-alcoholic fatty liver disease. Eligible patients who have non-alcoholic fatty liver disease are randomized to receive either nutritional education, omega-3 fatty acids containing DHA and EPA, or control groups. the main questions are: Does the Nutrition education affect body mass, liver enzyme and lipid profile in patient with non-alcoholic fatty liver disease? Does Omega-3 supplementation affect body mass, liver enzyme and lipid profile in patient with non-alcoholic fatty liver disease? The expected outcome will improvement in the laboratory liver tests, liver steatosis on ultrasound, and lipid profile and also decrease body weight.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 159 (actual)
- First submitted
- 1 Oct 2024
- Start date
- 29 Oct 2024
- Primary completion date
- 3 Mar 2025
- Lead sponsor
- Hawler Medical University
- Diseases
- Fatty liver disease (MASLD/MASH)
- NCT number
- NCT06627114
What you commit to
- Study type: Interventional
- Participants enrolled: 159
- From 29 Oct 2024 to the primary completion date, 3 Mar 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- supplementary intakes of n-3 PUFA within the previous 6 months.
- hormone therapy and use of drugs like amiodarone, methotrexate, and corticosteroid.
- The use of drugs known to be associated with liver steatosis (Drugs known to be capable of inducing steatosis and steatohepatitis can be divided into three broad groups: those that cause steatosis and steatohepatitis independently (e.g., amiodarone, perhexiline maleate); drugs which can precipitate latent NASH (e.g., tamoxifen); drugs which induce sporadic events of steatosis/steatohepatitis (e.g., carbamazepine).
Other illness
- chronic liver disease of other causes (autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, hereditary haemochromatosis, Wilson's disease, a1-anti-trypsin deficiency, coeliac disease).
- chronic disease such as cardiovascular, gastrointestinal, thyroid, renal, cancer or pancreatic that assessed by a specialist.
Other
- pregnancy or breastfeeding.
- three months.
Who the study is looking for
- Age between 18-74 years' old.
- Ability to use a mobile phone.
- Ultrasound examination diagnosed Patients with grade 1 and 2 non-alcoholic fatty liver disease.
Age in the registry: 18 years to 74 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hawler Medical University Coordinator of this site? Confirm its status | Erbil | Iraq | Unknown status |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.